

BIO-GENE ANNOUNCES APPOINTMENT OF HEAD OF REGULATORY AFFAIRS

- Highly experienced regulatory professional appointed to lead global registration program
- Extensive crop protection, consumer and professional pest control market experience gained while working for Bayer/Monsanto based in Europe
- Adds significant expertise and resource focused on managing registration programs for Flavocide[™] and Qcide[™] in collaboration with external service providers and commercial partners

Bio-Gene Technology Limited (ASX: BGT, 'Bio-Gene' or 'the 'Company'), an agtech development company enabling the next generation of novel insecticides, today announced the appointment of Sarah Driessens to the role of Head of Regulatory Affairs with global responsibilities.

Sarah has recently relocated to Australia, after previously being based in Brussels, Belgium. Sarah has a Masters in Biotechnology and worked for over 13 years with Monsanto (and subsequently Bayer after the Monsanto acquisition). Her main areas of focus were product registration for agricultural and consumer products across major geographic jurisdictions. She gained invaluable knowledge and experience working with key stakeholders and achieved notable success, especially in the European regulatory system.

Commenting on this announcement, Bio-Gene CEO, Richard Jagger said: "As announced at the time of our recent capital raise, we are now at a point where we need to add additional skill sets to the Bio-Gene team as we move along the commercialisation pathway. We are delighted that Sarah has chosen to join Bio-Gene. With her strong background in the regulatory process, Sarah brings an advanced level of technical and regulatory expertise that will ensure we manage the registration process of our Active Ingredients as efficiently as possible. Her experience with different regulatory bodies around the world is invaluable, and her command of multiple languages ensures good communication between Bio-Gene, our commercial partners, our registration study providers, and the various government regulatory bodies."

Sarah Driessens commented: "I'm delighted to be joining the Bio-Gene team and assist the company in the registration of its Active Ingredients, which is a crucial step in the commercialisation process. I feel my experience prepares me very well to ensure successful outcomes for Bio-Gene and its commercial partners."

Sarah will commence with Bio-Gene in late February 2022.

Approved for release by the Board of Directors.

- ENDS -

IR/Media

Rudi Michelson

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger Roger McPherson

Chief Executive Officer CFO & Company Secretary Monsoon Communications

P: 03 9068 1062 P: 03 9068 1062 P: 03 9620 3333

E: <u>bgt.info@bio-gene.com.au</u> E: <u>bgt.info@bio-gene.com.au</u> E: <u>rudim@monsoon.com.au</u>



About Bio-Gene Technology Ltd

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, animal health and consumer applications. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

Flavocide[™] and Qcide[™] are trademarks of Bio-Gene Technology Limited.